6.2.1.2.5. active surveillance - change treatment. men may remain whilst continue consent, life expectancy > ten years disease remains indolent. patient anxiety continued surveillance occurs around 10% patients recognised valid reason active treatment . alternative patients suitable continuing would offer psychological support reduce level anxiety . review patient reported factor influencing decision making, including thirteen qualitative papers 426 men, identified number factors influencing decision making considering as. among identified factors personal risk assessment, influence family friends, beliefs treatment well doctor system factors, underscoring importance individualised, relevant, clear information support decision making . recent population-based cohort study sweden regional differences uptake subsequent transition radical treatment concluded regional tradition high uptake associated lower probability transition radical treatment, failure . studies emphasise importance thorough information discussion patients pros/cons vs. active treatment already time diagnosis patients feel secure treatment choice avoid over-treatment. psa change alone, including psa-doubling time (psa-dt, < 3 years) change management based weak link grade progression rather trigger investigation. clear agreement detective consensus meeting well movember consensus group change psa lead repeat-mri repeat-biopsy. also agreed changes repeat mri needed confirmatory biopsy considering active treatment . histopathology criteria required trigger change management targeted biopsy era remain debated. mri-targeted biopsy induces grade shift isup grade group 2–3 cancers detected mri-targeted biopsy have, average, better prognosis detected systematic sampling (see section 5.2.4.2.6.4). increasing number men favourable intermediate-risk disease managed (see section 6.2.2.1), seems illogical use progression isup grade group 2 based targeted biopsies sole criterion reclassification. addition, acknowledged detective consensus meeting, number positive cores indicator tumour volume anymore targeted biopsies performed . agreement could reached pathological criteria required trigger change management detective consensus meeting . however, based findings sr incorporating 271 reclassification protocols, patients low-volume isup grade group 2 disease recruitment, increased systematic core positivity (> 3 cores involvement [> 50% per core]) repeat systematic biopsies using mri, reclassified . furthermore, study music registry half men favourable intermediate-risk prostate cancer remained free treatment five years diagnosis . results concordance detective movember consensus statements indicate men lose window cure similar short-term oncologic outcomes men undergoing up-front treatment oncologically safe option appropriately selected men favourable intermediate-risk prostate cancer. development comorbidities, resulting life expectancy less ten years merit new discussion patient may result decision transfer ww strategy. table 6.2.2: active surveillance screening-detected prostate cancer (large cohorts longer-term follow-up) studiesnmedian fu (mo)pt3 rp patients*10-year os (%)10-year css (%)adamy, et al. 2011 533-1,000484/24 (17%)9099godtman, et al. 2013 43972-8199.5klotz, et al. 2015 99377-8598.1tosoian, et al. 2020 1,81860-9399.9carlsson, et al. 2020 2,66452-94100total6,447–6,91461.8-88.699.3 * patients receiving active therapy following initial active surveillance.css = cancer-specific survival; fu = follow-up; mo = months; n = number patients; n.r. = reported; os = overall survival; rp = radical prostatectomy.